In spite of many issues, widespread adoption of prostate cancer screening using prostate specific antigen (PSA) testing has resulted in approximately 40% decreases in prostate cancer mortality from an epidemiologic perspective1, with approximately 45–70% of the decline attributable to PSA-based prostate cancer screening2,3. Here, KLK3 is linked to prostate carcinoma.